0001104659-18-025834.txt : 20180423
0001104659-18-025834.hdr.sgml : 20180423
20180423160546
ACCESSION NUMBER: 0001104659-18-025834
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180412
FILED AS OF DATE: 20180423
DATE AS OF CHANGE: 20180423
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Iannone Robert
CENTRAL INDEX KEY: 0001737329
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-12104
FILM NUMBER: 18768966
MAIL ADDRESS:
STREET 1: 300 THE AMERICAN WAY
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IMMUNOMEDICS INC
CENTRAL INDEX KEY: 0000722830
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 611009366
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 300 AMERICAN RD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
BUSINESS PHONE: 9736058200
MAIL ADDRESS:
STREET 1: 300 AMERICAN ROAD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
3
1
a3.xml
3
X0206
3
2018-04-12
0
0000722830
IMMUNOMEDICS INC
IMMU
0001737329
Iannone Robert
C/O IMMUNOMEDICS, INC
300 THE AMERICAN ROAD
MORRIS PLAINS
NJ
07950
0
1
0
0
See Remarks
Stock Options (right to buy)
14.46
2025-04-09
Common Stock, par value $0.01 per share
110000
D
Stock Options (right to buy)
14.46
2025-04-09
Common Stock, par value $0.01 per share
70000
D
Stock Options (right to buy)
14.46
2025-04-09
Common Stock, par value $0.01 per share
140000
D
The reporting person was granted stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options vest 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter.
The reporting person was granted performance-based vesting stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options will vest (i) as to 70,000 shares (a) 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter through the fourth anniversary of the date of grant (each date a "Vesting Date") and (b) subject to Immunomedics, Inc. common stock achieving a fair market value of $28.92 or higher based on the average closing price for the prior 15 consecutive trading days on such Vesting Date; and (ii) as to 70,000 shares (a) 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter through the fourth anniversary of the date of grant and (b) subject to Immunomedics, Inc. common stock achieving a fair market value of $43.38 or higher based on the average closing price for the prior 15 consecutive trading days on such Vesting Date.
If the performance-based vesting criteria of the stock options is not attained on an applicable Vesting Date, and to the extent such performance-based vesting criteria is subsequently attained, the applicable tranche of stock options may vest on the date such criteria is met.
Mr. Iannone is the Issuer's Chief Medical Officer. The Issuer's Board of Directors identified Mr. Iannone as a Section 16 Reporting Person on April 12, 2018.
/s/Robert Iannone
2018-04-23